Relay Therapeutics (RLAY) Stock Forecast & Price Target

Compare

542 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RLAY Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Relay

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RLAY Stock 12 Month Forecast

Average Price Target

$14.80

▲(84.31% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $14.80 with a high forecast of $17.00 and a low forecast of $13.00. The average price target represents a 84.31% change from the last price of $8.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","18":"$18","5.25":"$5.25","9.5":"$9.5","13.75":"$13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,5.25,9.5,13.75,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.4,8.138461538461538,8.876923076923077,9.615384615384615,10.353846153846154,11.092307692307692,11.830769230769231,12.569230769230769,13.307692307692307,14.046153846153846,14.784615384615385,15.523076923076923,16.26153846153846,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.4,7.969230769230769,8.538461538461538,9.107692307692307,9.676923076923078,10.246153846153845,10.815384615384616,11.384615384615385,11.953846153846154,12.523076923076923,13.092307692307692,13.661538461538463,14.23076923076923,{"y":14.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.4,7.830769230769231,8.261538461538462,8.692307692307693,9.123076923076923,9.553846153846154,9.984615384615385,10.415384615384616,10.846153846153847,11.276923076923076,11.707692307692309,12.138461538461538,12.569230769230769,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.67,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.47,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$14.80

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eva Fortea Verdejo

Wells Fargo

$6→$13

Buy

61.89%

Upside

Upgraded

12/12/25

Positive Report for Relay Therapeutics (RLAY) from Wells Fargo

Peter Lawson

Barclays

$17

Buy

111.71%

Upside

Reiterated

11/24/25

Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Robert Burns

H.C. Wainwright

$14

Buy

74.35%

Upside

Reiterated

11/10/25

Relay Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy RatingWe reiterate our Buy rating and 12‐month price target of $14 per share.

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/06/25

Analysts Are Bullish on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Relay Therapeutics (RLAY)We continue to view this as a prudent approach, as it will enable Relay to be fully funded through key objectives including: 1. Topline data for the Ph3 ReDiscover-2 trial and additional supportive BC combination trials (e.g., triplet studies) 2. Ph1 clinical POC data for RLY-2608 vascular malformations (VM; trial started in Q1:25)3. IND for their Fabry and NRAS programs (which will have phased starts) 4. Advancement of one preclinical program aimed at a high-value, previously "undruggable" target Lonnel Coats, former CEO of Dable, former CEO of Acceleron Pharma, were appointed to the Board of Directors; both bring extensive experience in late-stage drug development to aid the advancing pipeline.

Jason Gerberry

Bank of America Securities

$15

Buy

86.80%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/06/25

Analysts Conflicted on These Healthcare Names: Intellia Therapeutics (NASDAQ: NTLA), Relay Therapeutics (NASDAQ: RLAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Bradley Canino

Guggenheim

$15

Buy

86.80%

Upside

Reiterated

09/25/25

Andrew Berens

Leerink Partners

$12

Buy

49.44%

Upside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

136.61%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Silvan Tuerkcan

Citizens JMP

$12

Buy

49.44%

Upside

Reiterated

06/03/25

Citizens JMP reiterates Market Outperform Rating on Relay Therapeutics (RLAY)We reiterate our Market Outperform rating based on our continued confidence in RLY-2608, and maintain our DCFderived price target of $12.

Eric Joseph

J.P. Morgan

$21→$11

Buy

36.99%

Upside

Reiterated

05/13/25

Relay Therapeutics (RLAY) PT Lowered to $11 at JPMorganJPMorgan analyst Eric Joseph lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $11.00 (from $21.00) while maintaining a Overweight rating.

Salveen Richter

Goldman Sachs

$20→$18

Buy

124.16%

Upside

Reiterated

02/27/25

Relay Therapeutics (RLAY) PT Lowered to $18 at Goldman SachsGoldman Sachs analyst Salveen Richter lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $18.00 (from $20.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eva Fortea Verdejo

Wells Fargo

$6→$13

Buy

61.89%

Upside

Upgraded

12/12/25

Positive Report for Relay Therapeutics (RLAY) from Wells Fargo

Peter Lawson

Barclays

$17

Buy

111.71%

Upside

Reiterated

11/24/25

Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Robert Burns

H.C. Wainwright

$14

Buy

74.35%

Upside

Reiterated

11/10/25

Relay Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy RatingWe reiterate our Buy rating and 12‐month price target of $14 per share.

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/06/25

Jason Gerberry

Bank of America Securities

$15

Buy

86.80%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Matthew Biegler

Oppenheimer

―

Hold

―

Reiterated

11/06/25

Analysts Conflicted on These Healthcare Names: Intellia Therapeutics (NASDAQ: NTLA), Relay Therapeutics (NASDAQ: RLAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Bradley Canino

Guggenheim

$15

Buy

86.80%

Upside

Reiterated

09/25/25

Andrew Berens

Leerink Partners

$12

Buy

49.44%

Upside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

136.61%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Silvan Tuerkcan

Citizens JMP

$12

Buy

49.44%

Upside

Reiterated

06/03/25

Eric Joseph

J.P. Morgan

$21→$11

Buy

36.99%

Upside

Reiterated

05/13/25

Salveen Richter

Goldman Sachs

$20→$18

Buy

124.16%

Upside

Reiterated

02/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relay Therapeutics

1 Month

xxx

Success Rate

9/19 ratings generated profit

Average Return

-2.99%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.37% of your transactions generating a profit, with an average return of -2.99% per trade.

3 Months

xxx

Success Rate

6/13 ratings generated profit

Average Return

+0.65%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +0.65% per trade.

1 Year

Peter LawsonBarclays

Success Rate

8/16 ratings generated profit

Average Return

+39.34%

reiterated a buy rating 25 days ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +39.34% per trade.

2 Years

xxx

Success Rate

14/16 ratings generated profit

Average Return

+62.48%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +62.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RLAY Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RLAY has received 6 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 14.80.

Each month's total comprises the sum of three months' worth of ratings.

RLAY Financial Forecast

RLAY Earnings Forecast

Next quarter’s earnings estimate for RLAY is -$0.40 with a range of -$0.44 to -$0.20. The previous quarter’s EPS was -$0.43. RLAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Sales Forecast

Next quarter’s sales forecast for RLAY is $5.59M with a range of $0.00 to $30.00M. The previous quarter’s sales results were $0.00. RLAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Stock Forecast FAQ

What is RLAY’s average 12-month price target, according to analysts?

Based on analyst ratings, Relay Therapeutics’s 12-month average price target is 14.80.

What is RLAY’s upside potential, based on the analysts’ average price target?

Relay Therapeutics has 84.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RLAY a Buy, Sell or Hold?

Relay Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Relay Therapeutics’s price target?

The average price target for Relay Therapeutics is 14.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $13.00. The average price target represents 84.31% Increase from the current price of $8.03.

What do analysts say about Relay Therapeutics?

Relay Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of RLAY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Relay Therapeutics (RLAY) Stock Forecast & Price Target

RLAY Analyst Ratings

RLAY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Relay Therapeutics

RLAY Analyst Recommendation Trends

RLAY Financial Forecast

RLAY Earnings Forecast

RLAY Sales Forecast

RLAY Stock Forecast FAQ

Detailed List of Analyst Forecasts